| 摘要 |
The invention provides an isolated polypeptide comprising a variant amino acid sequence of SEQ ID NO: 1, or a fusion or derivative of said polypeptide, or a fusion of a said derivative thereof, wherein the polypeptide, fusion or derivative retains a biological activity of wild type IL-IRa. In one embodiment, the isolated polypeptide, fusion or derivative is or comprises a polypeptide variant of amino acid sequence SEQ ID NO: 1 comprising or consisting of substitutions at one or more of the following amino acid mutations of SEQ ID NO: 1: Q29K, P38Y, P38R, L42W, D47N, E52R, H54R, E90Y, Q129L, Q129N, M136N, M136D and Q149K. Also provided are pharmaceutical compositions of the above polypeptide, fusion or derivative, as well as uses of the same for treating a disease or condition capable of being treated by an agent which inhibits the function of IL-1 receptors. |
| 主权项 |
1. An isolated polypeptide comprising a variant of the amino acid sequence set forth in SEQ ID NO:1, wherein the polypeptide comprises at least 20 contiguous amino acids of SEQ ID NO:1, wherein the polypeptide is between 140 and 180 amino acids in length, wherein the variant amino acid sequence of SEQ ID NO:1 comprises an N84D amino acid substitution, wherein the polypeptide has an amino acid sequence which has at least 50% identity with SEQ ID NO:1, and wherein the polypeptide comprises one or more amino acid substitutions at one or more of positions 1 to 11, 51 to 55, and/or 89 to 93 relative SEQ ID NO:1. |
